We confirmed in vivo inhibition of canonical TGFβ signaling via the reduction in phosphorylated SMAD2/3 expressed in tumor-infiltrating CD45+ immune cells following isoform-specific and pan-TGFβ inhibition (Supplementary Fig. 8). This evidence concerns the gene PTPRC and neoplasm.